Efficient in vitro siRNA delivery and intramuscular gene silencing using PEG-modified PAMAM dendrimers

Molecular Pharmaceutics

Volumn 9, Issue 6, 2012, Pages 1812-1821

  Tang, Yin ^a,b   Li, Yang Bing ^a   Wang, Bo ^a   Lin, Ri Yuan ^a   Van Dongen, Mallory ^c   Zurcher, Danielle M ^c   Gu, Xiao Yan ^a   Banaszak Holl, Mark M ^c   Liu, George ^a,b   Qi, Rong ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

cytotoxicity; gene silencing effciency; in vitro and intramuscular siRNA delivery; PEG conjugated PAMAM dendrimer; RNase stability

Indexed keywords

DENDRIMER; FLUORESCEIN ISOTHIOCYANATE; GREEN FLUORESCENT PROTEIN; LIPOFECTAMINE; MACROGOL DERIVATIVE; POLYAMIDOAMINE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; C57BL 6 MOUSE; CELL STRAIN COS7; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GENE SILENCING; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; TRANSGENIC MOUSE; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANIMALS, NEWBORN; CELL LINE; COS CELLS; CRICETINAE; DENDRIMERS; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; GENE SILENCING; GREEN FLUORESCENT PROTEINS; MACROPHAGES; MICE; MICE, INBRED C57BL; MYOCYTES, SMOOTH MUSCLE; POLYETHYLENE GLYCOLS; RNA, SMALL INTERFERING;

EID: 84862022053     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp3001364     Document Type: Article

References (36)

1. Bernstein, E.; Caudy, A. A.; Hammond, S. M.; Hannon, G. J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001, 409, 363-6. (Pubitemid 32151243)
2. Castanotto, D.; Rossi, J. J. The promises and pitfalls of RNA-interference- based therapeutics. Nature 2009, 457, 426-33.
3. Wang, J.; Lu, Z.; Wientjes, M. G.; Au, J. L. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010, 12, 492-503.
4. Schiffelers, R. M.; van Rooy, I.; Storm, G. siRNA-mediated inhibition of angiogenesis. Expert Opin. Biol. Ther. 2005, 5, 359-68. (Pubitemid 40516746)
5. Olejniczak, M.; Polak, K.; Galka-Marciniak, P.; Krzyzosiak, W. J. Recent Advances in Understanding of the Immunological Off-Target Effects of siRNA. Curr. Gene Ther. 2011, 11, 532-43.
6. van de Water, F. M.; Boerman, O. C.; Wouterse, A. C.; Peters, J. G.; Russel, F. G.; Masereeuw, R. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab. Dispos. 2006, 34, 1393-7. (Pubitemid 44079881)
7. Gregoriadis, G.; Neerunjun, D. E. Control of the rate of hepatic uptake and catabolism of liposome-entrapped proteins injected into rats. Possible therapeutic applications. Eur. J. Biochem. 1974, 47, 179-85.
8. Takahashi, Y.; Yamaoka, K.; Nishikawa, M.; Takakura, Y. Quantitative and temporal analysis of gene silencing in tumor cells induced by small interfering RNA or short hairpin RNA expressed from plasmid vectors. J. Pharm. Sci. 2009, 98, 74-80.
9. Cheng, C. J.; Saltzman, W. M. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials 2011, 32, 6194-203.
10. Liu, X.; Rocchi, P.; Peng, L. Dendrimers as non-viral vectors for siRNA delivery. New J. Chem. 2012, 36, 256-63.
11. Philipp, A.; Zhao, X.; Tarcha, P.; Wagner, E.; Zintchenko, A. Hydrophobically modified oligoethylenimines as highly efficient transfection agents for siRNA delivery. Bioconjugate Chem. 2009, 20, 2055-61.
12. Minakuchi, Y.; Takeshita, F.; Kosaka, N.; Sasaki, H.; Yamamoto, Y.; Kouno, M.; Honma, K.; Nagahara, S.; Hanai, K.; Sano, A.; Kato, T.; Terada, M.; Ochiya, T. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 2004, 32, e109.
13. Spagnou, S.; Miller, A. D.; Keller, M. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 2004, 43, 13348-56. (Pubitemid 39391135)
14. Itaka, K.; Kanayama, N.; Nishiyama, N.; Jang, W. D.; Yamasaki, Y.; Nakamura, K.; Kawaguchi, H.; Kataoka, K. Supramolecular nanocarrier of siRNA from PEG-based block catiomer carrying diamine side chain with distinctive pKa directed to enhance intracellular gene silencing. J. Am. Chem. Soc. 2004, 126, 13612-3. (Pubitemid 39407229)
15. Jang, J. Y.; Choi, Y.; Jeon, Y. K.; Aung, K. C.; Kim, C. W. Overexpression of adenine nucleotide translocase 1 (ANT1) induces apoptosis and tumor regression in vivo. BMC Cancer 2008, 8, 160.
16. Urban-Klein, B.; Werth, S.; Abuharbeid, S.; Czubayko, F.; Aigner, A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 2005, 12, 461-6. (Pubitemid 40394299)
17. Grzelinski, M.; Urban-Klein, B.; Martens, T.; Lamszus, K.; Bakowsky, U.; Hobel, S.; Czubayko, F.; Aigner, A. RNA interference-mediated gene silencing of pleiotrophin through polyethyleniminecomplexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther. 2006, 17, 751-66. (Pubitemid 44100720)
18. Tidball, J. G.; Spencer, M. J. Skipping to new gene therapies for muscular dystrophy. Nat Med. 2003, 9, 997-8. (Pubitemid 37021775)
19. Aartsma-Rus, A.; van Ommen, G. J. Progress in therapeutic antisense applications for neuromuscular disorders. Eur. J. Hum. Genet. 2010, 18, 146-53.
20. Bortolanza, S.; Nonis, A.; Sanvito, F.; Maciotta, S.; Sitia, G.; Wei, J.; Torrente, Y.; Di Serio, C.; Chamberlain, J. R.; Gabellini, D. AAV6- mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophy. Mol. Ther. 2011, 19, 2055-64.
21. Kang, H.; DeLong, R.; Fisher, M. H.; Juliano, R. L. Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm. Res. 2005, 22, 2099-106. (Pubitemid 41821589)
22. Ouyang, D.; Zhang, H.; Parekh, H. S.; Smith, S. C. The effect of pH on PAMAM dendrimer-siRNA complexation: endosomal considerations as determined by molecular dynamics simulation. Biophys. Chem. 2011, 158, 126-33.
23. Zhou, J.; Wu, J.; Hafdi, N.; Behr, J. P.; Erbacher, P.; Peng, L. PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem. Commun. (Cambridge) 2006, 22, 2362-4. (Pubitemid 43846378)
24. Patil, M. L.; Zhang, M.; Betigeri, S.; Taratula, O.; He, H.; Minko, T. Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjugate Chem. 2008, 19, 1396-403. (Pubitemid 352032339)
25. Patil, M. L.; Zhang, M.; Taratula, O.; Garbuzenko, O. B.; He, H.; Minko, T. Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting. Biomacromolecules 2009, 10, 258-66.
26. Liu, X. X.; Rocchi, P.; Qu, F. Q.; Zheng, S. Q.; Liang, Z. C.; Gleave, M.; Iovanna, J.; Peng, L. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells. ChemMedChem 2009, 4, 1302-10.
27. Merkel, O. M.; Mintzer, M. A.; Librizzi, D.; Samsonova, O.; Dicke, T.; Sproat, B.; Garn, H.; Barth, P. J.; Simanek, E. E.; Kissel, T. Triazine dendrimers as nonviral vectors for in vitro and in vivo RNAi: the effects of peripheral groups and core structure on biological activity. Mol. Pharmaceutics 2010, 7, 969-83.
28. Qi, R.; Gao, Y.; Tang, Y.; He, R. R.; Liu, T. L.; He, Y.; Sun, S.; Li, B. Y.; Li, Y. B.; Liu, G. PEG-conjugated PAMAM dendrimers mediate efficient intramuscular gene expression. AAPS J. 2009, 11, 395-405.
29. Taratula, O.; Garbuzenko, O. B.; Kirkpatrick, P.; Pandya, I.; Savla, R.; Pozharov, V. P.; He, H.; Minko, T. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J. Controlled Release 2009, 140, 284-93.
30. Liu, X.; Liu, C.; Laurini, E.; Posocco, P.; Pricl, S.; Qu, F.; Rocchi, P.; Peng, L. Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine- core PAMAM dendrimer. Mol. Pharmaceutics 2012, 9, 470-81.
31. Majoros, I. J.; Keszler, B.; Woehler, S.; Bull, T.; Baker, J. R. Acetylation of Poly(amidoamine) Dendrimers. Macromolecules 2003, 36, 5526-29.
32. Aillon, K. L.; Xie, Y.; El-Gendy, N.; Berkland, C. J.; Forrest, M. L. Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv. Drug Delivery Rev. 2009, 61, 457-66.
33. Qi, R.; Mullen, D. G.; Baker, J. R.; Holl, M. M. The mechanism of polyplex internalization into cells: testing the GM1/caveolin-1 lipid raft mediated endocytosis pathway. Mol. Pharmaceutics 2010, 7, 267-79.
34. Karatasos, K.; Posocco, P.; Laurini, E.; Pricl, S. Poly- (amidoamine)-based dendrimer/siRNA complexation studied by computer simulations: effects of pH and generation on dendrimer structure and siRNA binding. Macromol. Biosci. 2012, 12, 225-40.
35. Khopade, A. J.; Caruso, F.; Tripathi, P.; Nagaich, S.; Jain, N. K. Effect of dendrimer on entrapment and release of bioactive from liposomes. Int. J. Pharm. 2002, 232, 157-62. (Pubitemid 34076761)
36. Rozema, D. B.; Lewis, D. L.; Wakefield, D. H.; Wong, S. C.; Klein, J. J.; Roesch, P. L.; Bertin, S. L.; Reppen, T. W.; Chu, Q.; Blokhin, A. V.; Hagstrom, J. E.; Wolff, J. A. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 12982-7. (Pubitemid 351737577)